- Roche divulges new data that demonstrate Ocrevus (ocrelizumab) is a highly effective treatment option for people with RRMS who experienced a suboptimal response to their prior DMT. In open-label P-IIIb CASTING study, 75% of patients with RRMS and suboptimal response to prior treatment had no evidence of disease activity 2yrs. after switching to Ocrevus
- The analysis showed the proportion of patients achieving NEDA remained consistently high across all measured patient subgroups. Additionally, patients treated with Ocrevus experienced an improvement in most symptoms measured by SymptoMScreen after 2yrs.
- A 97% treatment persistence for Ocrevus patients at 18mos., and strong adherence to infusions every 6mos., was seen in an interim analysis of 1,600+ patients in the ongoing German CONFIDENCE study. OCREVUS is the first and only treatment approved for both RMS and PPMS and now 170,000+ people have been treated with Ocrevus globally in the clinical trial and real-world settings; favorable benefit-risk profile remains consistent over 7yrs.
Click here to read full press release/ article | Ref: Roche | Image: StraitTimes